Robert A. Newman is an American pharmacologist specializing in molecular biology, drug development, and immunology.

In 1984 he was appointed as chief of the Section of Pharmacology and Experimental Therapeutics at the University of Texas M.D.

[1] In 1988, Newman began studies of the anticancer potential of extracts and components of Nerium oleander research that was initially begun by Turkish Doctor H. Ziya Ozel.

[2] Newman has published over 320 articles dealing with the preclinical and clinical pharmacology, toxicology, and development of therapies for the prevention and treatment of malignant diseases.

His research and publications have detailed the novel value of oleandrin and oleander extracts in prevention of stroke mediated ischemic injury to brain tissue and more recently against key viruses (e.g. Ebola, HTLV-1, HIV).